Novo to buy mid-stage heart failure biotech Cardior for up to $1.1B - Endpoints News

Novo Nordisk plans to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion to boost its presence in cardiovascular disease, the Danish drug giant said Monday morning. The move comes three weeks after Novo's obesityAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute